Read by QxMD icon Read

Neurodegenerative Disease Management

Werner Poewe, K Ray Chaudhuri, Lars Bergmann, Angelo Antonini
AIM: To evaluate long-term effects of levodopa-carbidopa intestinal gel on dyskinesia burden. PATIENTS & METHODS: Posthoc analysis of the GLORIA registry assessed subgroups of advanced Parkinson's disease patients with <4 and ≥4 h/day of levodopa-induced dyskinesia at baseline. RESULTS & CONCLUSIONS: Mean dyskinesia duration significantly (p < 0.0001) decreased by 3.5 h in patients with ≥4 h baseline dyskinesia; conversely, dyskinesia duration increased by 1...
December 14, 2018: Neurodegenerative Disease Management
Arnt V Kristen, Senda Ajroud-Driss, Isabel Conceição, Peter Gorevic, Theodoros Kyriakides, Laura Obici
Hereditary transthyretin-mediated amyloidosis is a rapidly progressive, heterogeneous disease caused by the accumulation of misfolded transthyretin protein as amyloid fibrils at multiple sites, and is characterized by peripheral sensorimotor neuropathy, autonomic neuropathy and/or cardiomyopathy. Current treatment options have limited efficacy and often do not prevent disease progression. Patisiran is a novel RNA interference therapeutic that specifically reduces production of both wild-type and mutant transthyretin protein...
November 27, 2018: Neurodegenerative Disease Management
Volker Limmroth, Iason Bartzokis, Eckhard Bonmann, Patrick Kusel, Thomas Schreiner, Markus Schürks
Adherence to long-term treatment in chronic diseases such as multiple sclerosis is challenging. Many disease-modifying drugs (DMDs) for MS need to be injected. Injection devices may improve satisfaction with the injection procedure and boost adherence. Meeting patients' needs in handling and design of autoinjectors and other supporting elements may be key to successful therapy. The BETACONNECT™ system is a platform-based approach in DMD therapy. It combines autoinjector technology with digital tools to support patient self-management and facilitate communication between patients and healthcare providers...
October 3, 2018: Neurodegenerative Disease Management
Linda Lee, Karen Slonim, Loretta M Hillier, Stephanie K Lu, Jennifer Lee
AIMS: To understand persons with dementia (PWD) and care partners' experiences with the Primary Care Collaborative Memory Clinic (PCCMC) care model. METHODS: Interviews were conducted with a purposeful sample of PWD (n = 12) and care partners (N = 16) to identify their perspectives of care received in the clinic and suggestions for improvement. RESULTS: PWD and care partners were satisfied with care received within the PCCMC, had positive interactions with and perceived a strong sense of support from team members and felt listened to; the necessity of cognitive testing was recognized but disliked...
December 2018: Neurodegenerative Disease Management
Philippe Huot
No abstract text is available yet for this article.
December 2018: Neurodegenerative Disease Management
Viraj Bharambe, Andrew J Larner
AIM: To examine features associated with functional cognitive disorders (FCDs) compared with neurological cognitive disorders (dementia, mild cognitive impairment, transient amnesias) in consecutive patients referred to a secondary care cognitive disorders clinic. METHODS: Patients diagnosed with either neurological cognitive disorder or FCD were compared by demographic (age, gender, handedness, referral source) and clinical features (family history of dementia, clinical signs, Likert screening measure of subjective memory complaint, mini-Addenbrooke's Cognitive Examination)...
December 2018: Neurodegenerative Disease Management
Samar S Ayache, Moussa A Chalah
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, characterized by chronic inflammation, demyelination, synaptopathy and neurodegeneration. Patients may exhibit sensory, motor, cognitive, emotional and behavioral symptoms throughout their disease process. Nowadays, the challenge is to find optimal treatment for MS symptoms, especially that available pharmacological interventions are faced by modest therapeutic outcomes and numerous side effects. Thus, finding alternative strategies might be of help in this context...
December 2018: Neurodegenerative Disease Management
Hannah Brown, Simone Gabriele, Joanna White
OBJECTIVE: To assess factors used in treatment decision-making for relapsing-remitting multiple sclerosis in both the 5EU (UK/Germany/France/Italy/Spain) and the USA. METHODS: Data were abstracted from the Ipsos Healthcare Global Multiple Sclerosis Therapy Monitor (data abstracted September-December, 2015-2017) a bi-annual online chart-review study of patients with multiple sclerosis. RESULTS: Treatment choices were primarily due to efficacy for relapses while convenience factors, other than oral administration, were uncommon...
December 2018: Neurodegenerative Disease Management
Danko Coric, Jenny A Nij Bijvank, Laurentius J van Rijn, Axel Petzold, Lisanne J Balk
In this review, a current overview is provided of how optical coherence tomography and infrared oculography can aid in assessing the visual system and CNS in multiple sclerosis (MS). Both afferent and efferent visual disorders are common in MS and visual complaints can have a tremendous impact on daily functioning. Optical coherence tomography and infrared oculography can detect and quantify visual disorders with high accuracy, but could also serve as quantitative markers for inflammation, neurodegeneration and network changes including cognitive decline in MS patients...
October 2018: Neurodegenerative Disease Management
Robert W Motl, Brian M Sandroff, Edward McAuley
AIM: This study examined the trajectory and pattern of naturally occurring change in perceived walking impairment over a 30-month period in relapsing-remitting multiple sclerosis (RRMS). PATIENTS & METHODS: Two hundred and sixty-nine persons with RRMS completed the 12-item Multiple Sclerosis Walking Scale (MSWS-12) every 6 months over a 30-month period. Data were analyzed using latent growth curve modeling and latent class growth curve modeling. RESULTS: Latent growth curve modeling demonstrated that a linear trajectory adequately described the group-level pattern of change in MSWS-12 scores over time...
October 2018: Neurodegenerative Disease Management
Yusuf A Rajabally
No abstract text is available yet for this article.
October 2018: Neurodegenerative Disease Management
Khashayar Dashtipour, Ali Tafreshi, Jessica Lee, Brianna Crawley
The prevalence of speech disorders among individuals with Parkinson's disease (PD) has been reported to be as high as 89%. Speech impairment in PD results from a combination of motor and nonmotor deficits. The production of speech depends upon the coordination of various motor activities: respiration, phonation, articulation, resonance and prosody. A speech disorder is defined as impairment in any of its inter-related components. Despite the high prevalence of speech disorders in PD, only 3-4% receive speech treatment...
October 2018: Neurodegenerative Disease Management
Andrew J Larner
AIM: To undertake a diagnostic test accuracy study of the Mini-Mental State Examination (MMSE) administered in primary care to patients who were subsequently referred to a cognitive disorders clinic in secondary care (n = 72). METHODS: MMSE scores from primary care were cross-classified with reference standard diagnoses made in secondary care, blind to MMSE score, in order to calculate standard measures of discrimination (including sensitivity and specificity, positive and negative predictive values)...
October 2018: Neurodegenerative Disease Management
Kerri S Rawson, Patricia Creel, Lizbeth Templin, Adam P Horin, Ryan P Duncan, Gammon M Earhart
AIM: In this pilot study, we evaluated the feasibility, safety and preliminary efficacy of a 6-week, community-based group intervention designed to reduce freezing of gait (FOG) for people with Parkinson's disease (PD). METHODS: Seven people with PD completed 'FOG Boot Camp' provided by the St. Louis Chapter of the American Parkinson Disease Association. We recorded attendance, participant's acceptance of the intervention and adverse events during classes. Pre and post-tests included measures of freezing, balance, motor severity, quality-of-life and gait speed...
October 2018: Neurodegenerative Disease Management
Annakaisa Haapasalo, Mikko Hiltunen
The international Kuopio Alzheimer Symposium was organized by the University of Eastern Finland in Kuopio, Finland on June 6-8, 2018 for the 8th time. Approximately 300 researchers in the fields of neuroscience and neurology from 12 different countries around the world gathered to Kuopio to hear and discuss about the latest insights into the mechanisms and comorbidities and novel approaches for diagnosis, prediction, prevention and therapies of Alzheimer's disease and other neurodegenerative diseases. The 2-day international program on June 7-8 included a keynote session, five oral scientific sessions and a poster session...
October 2018: Neurodegenerative Disease Management
Bruce D Trapp, Daniel Ontaneda
Dr Bruce Trapp and Dr Daniel Ontaneda speak to Laura Dormer, Commissioning Editor: Bruce D Trapp, PhD, is a Chair of the Department of Neurosciences at the Lerner Research Institute, Cleveland Clinic (OH, USA) and Professor of Molecular Medicine at Case Western Reserve University (OH, USA). Dr Trapp received his PhD from Loyola University Stritch School of Medicine in Chicago (IL, USA). Dr Trapp's research investigates the cause of neurological disability in multiple sclerosis patients, cellular mechanism of brain repair in neurodegenerative diseases and the molecular biology of myelination in the central and peripheral nervous systems...
September 14, 2018: Neurodegenerative Disease Management
Theresa Zesiewicz, Jason L Salemi, Susan Perlman, Kelly L Sullivan, Jessica D Shaw, Yangxin Huang, Charles Isaacs, Clifton Gooch, David R Lynch, Matthew B Klein
AIM: To evaluate the safety and clinical effects of EPI-743 in Friedreich's ataxia patients. EPI-743 is a compound that targets oxidoreductase enzymes essential for redox control of metabolism. METHODS: We conducted a multicenter trial that evaluated EPI-743 during a 6-month placebo-controlled phase, followed by an 18-month open-label phase. End points included low-contrast visual acuity and the Friedreich's Ataxia Rating Scale. RESULTS/CONCLUSION: EPI-743 was demonstrated to be safe and well tolerated...
August 2018: Neurodegenerative Disease Management
Mahmoud A Alomari, Hanan Khalil, Omar F Khabour, Robert Wood
AIM: The current study examined the relationship of handgrip, leg and arm neuromuscular performance with cardiovascular function in patients with Parkinson's disease (PD). MATERIALS & METHODS: Blood pressure, vascular measures and handgrip, shoulder and leg neuromuscular performance were obtained in PD persons and healthy controls. RESULTS: The data reveal that muscular and cardiovascular functions are altered (p < 0.05) in PD. Most importantly, regression indicates that altered central and peripheral cardiovascular function measures demonstrate a moderately strong relationship (p < 0...
August 2018: Neurodegenerative Disease Management
Josef Finsterer
No abstract text is available yet for this article.
August 2018: Neurodegenerative Disease Management
Rajesh R Tampi, Juan J Young, Deena J Tampi
No abstract text is available yet for this article.
August 2018: Neurodegenerative Disease Management
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"